en · de · es · fr · pt
cjc-1295-notes.peptides9002.com › Blog › Receptor Action And Pharmacokinetics — Explained

Receptor Action And Pharmacokinetics — Explained

By Editorial Desk · published 2025-12-01 · last reviewed 2026-01-01 · Blog

The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-01-01 and is reviewed periodically as new material appears.

Receptor Action and Pharmacokinetics

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Compound Identity and Development History

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

Cjc-1295 at a glance

PropertyValueNotes
Primary targetGHRH receptorG-protein-coupled receptor on pituitary somatotrophs
Half-life, long-acting formSeveral daysExtended by covalent albumin binding
Half-life, short formAbout 30 minutesCleared rapidly by peptidases and kidneys
Route in studiesSubcutaneous injectionUsed in the published human trials
Main measured effectRise in GH and IGF-1Surrogate markers rather than clinical endpoints

Receptor Action and Clearance

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Related pages on this site

Background and Naming Conventions

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

Notes from published material

affected relative pair Any pair of organisms which are related genetically and both affected by the same trait. For example, two cousins who both have blue eyes are an affected relative pair since they are both affected by the allele that codes for blue eyes.

If a mutation is present in a germ cell, it can give rise to offspring that carries the mutation in all of its cells. This is the case in hereditary diseases. In particular, if there is a mutation in a DNA repair gene within a germ cell, humans carrying such germline mutations may have an increased risk of cancer. A list of 34 such germline mutations is given in the article DNA repair-deficiency disorder. An example of one is albinism, a mutation that occurs in the OCA1 or OCA2 gene. Individuals with this disorder are more prone to many types of cancers, other disorders and have impaired vision. DNA damage can cause an error when the DNA is replicated, and this error of replication can cause a gene mutation that, in turn, could cause a genetic disorder. DNA damages are repaired by the DNA repair system of the cell. Each cell has a number of pathways through which enzymes recognize and repair damages in DNA. Because DNA can be damaged in many ways, the process of DNA repair is an important way in which the body protects itself from disease. Once DNA damage has given rise to a mutation, the mutation cannot be repaired.

'Cyberwarfare' is used in a broad context to denote interstate use of technological force within computer networks in which information is stored, shared, or communicated online.Raymond Charles Parks and David P. Duggan focused on analyzing cyberwarfare in terms of computer networks and pointed out that "Cyberwarfare is a combination of computer network attack and defense and special technical operations." According to this perspective, the notion of cyber warfare brings a new paradigm into military doctrine. Paulo Shakarian and colleagues put forward the following definition of "cyber war" in 2013, drawing on Clausewitz's definition of war: "War is the continuation of politics by other means":Cyber war is an extension of policy by actions taken in cyber space by state or nonstate actors that constitute a serious threat to a nation's security or are conducted in response to a perceived threat against a nation's security. Taddeo offered the following definition in 2012:

== Equations == The Beer–Lambert law states that there is a logarithmic dependence between the transmission (or transmissivity), T, of light through a substance and the product of the absorption coefficient of the substance, α, and the distance the light travels through the material (i.e. the path length), ℓ. The absorption coefficient can, in turn, be written as a product of either a molar absorptivity of the absorber, ε, and the concentration c of absorbing species in the material, or an absorption cross section, σ, and the (number) density N of absorbers. (see Beer Lambert Law link for full derivation)

Sources: en.wikipedia.org

Background from the literature

==== Antithrombin ==== Antithrombin is a serine protease inhibitor (serpin) that degrades the serine proteases: thrombin, FIXa, FXa, FXIa, and FXIIa. It is constantly active, but its adhesion to these factors is increased by the presence of heparan sulfate (a glycosaminoglycan) or the administration of heparins (different heparinoids increase affinity to FXa, thrombin, or both). Quantitative or qualitative deficiency of antithrombin (inborn or acquired, e.g., in proteinuria) leads to thrombophilia.

== Sunderland's classification == In 1951, Sunderland expanded Seddon's classification to five degrees. The first two are the same as Seddon's. With each degree, the severity of the injury increases and has larger structural disruption and poorer prognosis. Sunderland's third-degree and fourth-degree are included within Seddon's axonotmensis. Sunderland's third-degree is nerve fiber interruption. This includes an endoneurium lesion with disruption of the axon and endoneurium, but an intact epineurium and perineurium. Recovery from a third-degree injury may require surgical intervention due to misdirected regeneration that is caused by endoneurial damage. In fourth-degree injury, only the epineurium remain intact, and a complete block to axonal regeneration could occur, requiring surgical repair. Sunderland's fifth-degree is included within Seddon's neurotmesis. Fifth-degree lesion is a complete transection of the nerve, including the epineurium. Recovery requires appropriate surgical treatment since there is no spontaneous recovery expected.

Resveratrol and related polyphenols (usually as "grape seed extract") are often included. Yohimbine has also been used as an ingredient (often as Pausinystalia johimbe extract), as a supposed testosterone booster and fat-loss agent, but it has been associated with dangerous side effects, and is also a prescription medicine in many countries. Phenylpiracetam is also sometimes used as an ingredient for its nootropic and stimulant effects. Capsaicin is sometimes used as an ingredient in gelcap pre-workout formulations, both as a supoosed weight loss aid and for improvement of endurance. Plant extracts, such as Ginkgo biloba, Panax ginseng, Rhodiola rosea and Huperzine A (from Huperzia serrata), are sometimes included for their supposed ability to improve endurance and mental clarity, despite limited evidence for efficacy. Ecdysteroids, such as ecdysterone and turkesterone, and other plant derived steroid like compounds such as 5α-Hydroxylaxogenin are sometimes used as ingredients, despite inconclusive results as to their supposed anabolic effects. Prohormones such as DHEA, CDMA, 1-androstenediol and 7α-methyl-19-norandrostenedione were widely used in pre-workout formulations prior to 2014 when they were formally banned. These compounds are not anabolic agents in their own right, but are metabolised into anabolic steroids of a type which at the time were not restricted.

Triggering PD-1, expressed on monocytes and up-regulated upon monocytes activation, by its ligand PD-L1 induces IL-10 production which inhibits CD4 T-cell function. In mice, expression of this gene is induced in the thymus when anti-CD3 antibodies are injected and large numbers of thymocytes undergo apoptosis. Mice deficient for this gene bred on a BALB/c background developed dilated cardiomyopathy and died from congestive heart failure. These studies suggest that this gene product may also be important in T cell function and contribute to the prevention of autoimmune diseases. Overexpression of PD1 on CD8+ T cells is one of the indicators of T-cell exhaustion (e.g. in chronic infection or cancer).

Systemic Lupus Erythematosus (SLE) Systemic Sclerosis (SS) Primary Sjögren's Syndrome (pSS) Raynaud's phenomenon Scleroderma Rheumatoid Arthritis The addition of anti-U1 RNP antibodies reveals that many autoimmune diseases share symptoms such as joint pain, fatigue, and Raynaud's phenomenon. The pathogenic role of anti-nRNP antibodies in these diseases varies, and their presence may only reflect immune system deregulation rather than being the direct cause of disease symptoms. Yet, they have served as valuable biomarkers.

Sources: en.wikipedia.org

Further detail

Marsha Linehan's biosocial developmental theory posits that BPD arises from the interaction between a child's inherent emotional vulnerability and an invalidating environment—an environment characterized by the neglect, ridicule, dismissal, or discouragement of a child's emotions and needs. Due to it drawing on attachment theory, which centers Western nuclear family norms, the diagnosis of BPD has been critiqued by Indigenous and decolonial scholars for possibly pathologizing Indigenous and collectivist cultural forms of caregiving.

Level instrumentation determines the height of liquids by measuring the position of a gas/liquid or liquid/liquid interface within the vessel or tank. Such interfaces include oil/gas, oil/water, condensate/water, glycol/condensate, etc. Local indication (LI) includes sight glasses which show the liquid level directly through a vertical glass tube attached to the vessel/tank. Phase interfaces are maintained at a constant level by level transmitters (LT) transmitting a signal to a level controller (LIC) which compares the measured value with the desired set point. The difference is sent as a signal to a level control valve (LCV) on the liquid outlet from the vessel. As the level rises the controller acts to open the valve to draw off liquid to reduce the level. Similarly as the levels fall the controller acts to close the LCV to reduce outflow of fluid. Some vessels store liquid until it is pumped out. The controller (LIC) acts to start and stop the pump within a specified band. For example, it may start the pump when the level rises to 0.6 m and stop the pump when the level falls to 0.4 m. High and low level alarms (LAH and LAL) warn operating personnel that levels are outside predefined limits. Further deviation (LAHH and LALL) initiates a shutdown either to close emergency shutdown valves (ESDV) on the inlet to the vessel or on the liquid outlet lines. As with high and low pressure instrumentation the shutdown function comprises an independent measurement loop to prevent a common mode failure.

Experiments confirm that UV-B light is necessary for parietin synthesis—under controlled conditions, thalli exposed only to photosynthetically active radiation (PAR) regenerated 12% of their parietin, while those exposed to UV-B restored 35%. Despite lower UV-B levels in Arctic environments, X. parietina maintains high parietin concentrations, suggesting that additional environmental factors regulate its production. Seasonal field studies show that parietin levels in Xanthoria parietina follow an annual cycle. In naturally occurring populations, concentrations were lowest in winter and nearly doubled by the summer solstice. This pattern mirrors seasonal shifts in UV-B radiation, suggesting that parietin synthesis is rapidly upregulated in spring to shield the photobiont from excess light and declines more gradually in autumn as irradiance decreases. In addition to parietin, X. parietina produces several related anthraquinones, including fallacinol (also called teloschistin), fallacinal, emodin, and parietinic acid. Fallacinol and fallacinal are minor anthraquinones, while emodin is another orange pigment found in some lichens. These compounds contribute to the chemical profile of X. parietina and have been investigated in phytochemical studies. Recent research (2023) has explored X. parietina as a natural source of anthraquinones for synthesizing pharmaceutical derivatives, such as O-methylated and acylated anthraquinones. X. parietina also produces the secondary metabolite 2-methoxy-4,5,7-trihydroxy-anthraquinone, as well as tocopherol and ergosterol.

Peptide-methionine (S)-S-oxide reductase (EC 1.8.4.11, MsrA, methionine sulphoxide reductase A, methionine S-oxide reductase (S-form oxidizing), methionine sulfoxide reductase A, peptide methionine sulfoxide reductase, formerly protein-methionine-S-oxide reductase) is an enzyme with systematic name peptide-L-methionine:thioredoxin-disulfide S-oxidoreductase (L-methionine (S)-S-oxide-forming). This enzyme catalyses the following chemical reaction

Sources: en.wikipedia.org

Frequently asked questions

How does CJC-1295 raise growth hormone levels?

It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.

Why does the DAC form last longer?

The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.

What remains uncertain about its effects?

Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.

What is CJC-1295?

It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.

Network